Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

Phase 1 Terminated 6 enrolled Oregon Health and Science University Portland VA Medical Center · collab

RandomizedCrossoverQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy of buspirone in combination with amantadine in reducing levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).

Timeline

Start: 2016-01
Primary completion: 2021-02-23
Completion: 2021-02-23

Publications

McFarthing K, Prakash N, Simuni T. CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA. J Parkinsons Dis. 2019;9(3):449-465. doi: 10.3233/JPD-199002. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Buspirone	Small molecule	10 mg	—

Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

Summary

Timeline

Publications

Drugs

Indications